<DOC>
	<DOCNO>NCT00490568</DOCNO>
	<brief_summary>This Phase III , multicenter , open-label extension , single-group study male female outpatient mild-to-moderate Alzheimer 's disease ( AD ) complete either AVA102670 AVA102672 . All subject receive rosiglitazone extended-release ( RSG XR ) 4mg daily first 4 week study follow 8mg RSG XR adjunctive therapy exist dose acetylcholinesterase inhibitor . Subject participation last one 5 condition applies . After 52-week open-label treatment phase , subject attend final Follow-Up Visit 6 week end treatment . The primary objective study evaluate long-term safety tolerability RSG XR subject mild-to-moderate AD complete either AVA102670 AVA102672 . The secondary objective study explore long-term efficacy RSG XR term cognitive function overall clinical response function apolipoprotein E ( APOE ) e4 allele status .</brief_summary>
	<brief_title>Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Successful completion AVA102670 AVA102672 without safety tolerability issue . Regular caregiver . Exclusion criterion : Congestive Heart Failure ( NYHA 14 ) , clinically significant peripheral edema , neurological condition might disqualify participation . SAE , clinically significant laboratory abnormality significant cardiovascular event prior study .</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>91 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>cognition</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Rosiglitazone extended-release ( XR )</keyword>
	<keyword>safety</keyword>
	<keyword>adjunctive therapy</keyword>
	<keyword>BRL-049653</keyword>
	<keyword>tolerability</keyword>
	<keyword>open-label extension</keyword>
</DOC>